Following FDA’s complete response letter, HGS and Novartis have jointly decided to terminate the development of Zalbin.
Zalbin is a genetic fusion of human albumin and interferon alfa created using proprietary HGS albumin-fusion technology.
Earlier in 2006, HGS and Novartis had entered into a co-development and commercialisation agreement to co-commercialise albinterferon alfa-2b in the US under the brand name Zalbin.